To determine whether the excessive activation of TAK1-JNK/p38 is required for GCN5 overexpression-mediated cardiac hypertrophy, 5Z-7-oxozeaenol and NG25 were used as specific inhibitors of TAK1 in vivo and in vitro, respectively [27]. The gene discussed is MAP3K7; the disease is cardiac hypertrophy.